PCM
MYGN icon

Penserra Capital Management’s Myriad Genetics MYGN Stock Holding History

Penserra Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,785
Closed -$57K – 1482
2021
Q3 		$57K Buy
1,785
+30
+2% +$996 ﹤0.01% 1018
2021
Q2 		$53K Buy
1,755
+55
+3% +$1.59K ﹤0.01% 984
2021
Q1 		$51K Sell
1,700
-50
-3% -$1.42K ﹤0.01% 809
2020
Q4 		$34K Buy
1,750
+1,112
+174% +$18K ﹤0.01% 751
2020
Q3 		$8K Buy
+638
New +$8.07K ﹤0.01% 837

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Penserra Capital Management's MYGN Position: Q4 2021 in Review

Penserra Capital Management sold out of Myriad Genetics (MYGN) in Q4 2021, closing a stake of 1,785 shares — an estimated $57K sold.

Penserra Capital Management first reported a position in MYGN in Q3 2020 and held it in 5 quarters. The position peaked at $57K in Q3 2021. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2021.

  • Penserra Capital Management reported no remaining Myriad Genetics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,785 Myriad Genetics shares in Q4 2021, an estimated $57K.
  • Penserra Capital Management first reported a position in Myriad Genetics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Myriad Genetics position peaked at $57K in Q3 2021.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.